OCULAR THERAPEUTIX, INC Operating Leases, Rent Expense
OCULAR THERAPEUTIX, INC (OCUL) reported Operating Leases, Rent Expense of $1.79 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-03-07
- OCULAR THERAPEUTIX, INC operating leases, rent expense for the quarter ending 2017-12-31 was $406.00K, a 19.12% decline year-over-year.
- OCULAR THERAPEUTIX, INC operating leases, rent expense for the quarter ending 2017-09-30 was $366.00K, a 88.66% increase year-over-year.
- OCULAR THERAPEUTIX, INC operating leases, rent expense for the quarter ending 2017-06-30 was $466.00K, a 140.21% increase year-over-year.
- OCULAR THERAPEUTIX, INC operating leases, rent expense for the quarter ending 2017-03-31 was $496.00K, a 159.69% increase year-over-year.
- OCULAR THERAPEUTIX, INC operating leases, rent expense for fiscal 2018 was $1.79M, a 3.17% increase from fiscal 2017.
- OCULAR THERAPEUTIX, INC operating leases, rent expense for fiscal 2017 was $1.73M, a 59.87% increase from fiscal 2016.
- OCULAR THERAPEUTIX, INC operating leases, rent expense for fiscal 2016 was $1.08M, a 39.33% increase from fiscal 2015.
- OCULAR THERAPEUTIX, INC operating leases, rent expense for fiscal 2015 was $778.00K, a 19.88% increase from fiscal 2014.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2018-12-31 | $1.79M 10-K · filed 2019-03-07 | |||
| 2017-12-31 | $406.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $772.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.24M derived: sum of 3 quarters · filed 2019-03-07 | $1.73M 10-K · filed 2019-03-07 |
| 2017-09-30 | $366.00K 10-Q · filed 2017-11-07 | $832.00K derived: sum of 2 quarters · filed 2017-11-07 | $1.33M 10-Q · filed 2017-11-07 | $1.83M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $466.00K 10-Q · filed 2017-08-08 | $961.00K 10-Q · filed 2017-08-08 | $1.46M derived: sum of 3 quarters · filed 2019-03-07 | $1.66M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $496.00K 10-Q · filed 2017-05-05 | $998.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.19M derived: sum of 3 quarters · filed 2019-03-07 | $1.39M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $502.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $696.00K derived: sum of 2 quarters · filed 2019-03-07 | $890.00K derived: sum of 3 quarters · filed 2019-03-07 | $1.08M 10-K · filed 2019-03-07 |
| 2016-09-30 | $194.00K 10-Q · filed 2017-11-07 | $388.00K derived: sum of 2 quarters · filed 2017-11-07 | $582.00K 10-Q · filed 2017-11-07 | $774.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $194.00K 10-Q · filed 2016-08-09 | $388.00K 10-Q · filed 2017-08-08 | $580.00K derived: sum of 3 quarters · filed 2018-03-08 | $773.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $191.00K 10-Q · filed 2017-05-05 | $386.00K derived: sum of 2 quarters · filed 2018-03-08 | $579.00K derived: sum of 3 quarters · filed 2018-03-08 | $774.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $388.00K derived: sum of 2 quarters · filed 2018-03-08 | $583.00K derived: sum of 3 quarters · filed 2018-03-08 | $778.00K 10-K · filed 2018-03-08 |
| 2015-09-30 | $193.00K 10-Q · filed 2016-11-09 | $388.00K derived: sum of 2 quarters · filed 2016-11-09 | $583.00K 10-Q · filed 2016-11-09 | $777.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $195.00K 10-Q · filed 2016-08-09 | $390.00K 10-Q · filed 2016-08-09 | $584.00K derived: sum of 3 quarters · filed 2017-03-10 | $780.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $195.00K 10-Q · filed 2016-05-10 | $389.00K derived: sum of 2 quarters · filed 2017-03-10 | $585.00K derived: sum of 3 quarters · filed 2017-03-10 | $734.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $390.00K derived: sum of 2 quarters · filed 2017-03-10 | $539.00K derived: sum of 3 quarters · filed 2017-03-10 | $649.00K 10-K · filed 2017-03-10 |
| 2014-09-30 | $196.00K 10-Q · filed 2015-11-10 | $345.00K derived: sum of 2 quarters · filed 2015-11-10 | $455.00K 10-Q · filed 2015-11-10 | $566.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $149.00K 10-Q · filed 2015-08-10 | $259.00K 10-Q · filed 2015-08-10 | $370.00K derived: sum of 3 quarters · filed 2016-03-10 | $484.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $111.00K 10-Q · filed 2015-05-15 | $221.00K derived: sum of 2 quarters · filed 2016-03-10 | $335.00K derived: sum of 3 quarters · filed 2016-03-10 | $447.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $224.00K derived: sum of 2 quarters · filed 2016-03-10 | $336.00K derived: sum of 3 quarters · filed 2016-03-10 | $448.00K 10-K · filed 2016-03-10 |
| 2013-09-30 | $114.00K 10-Q · filed 2014-11-12 | $226.00K derived: sum of 2 quarters · filed 2014-11-12 | $338.00K 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $112.00K 10-Q · filed 2014-08-29 | $224.00K 10-Q · filed 2014-08-29 | ||
| 2012-12-31 | $436.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |